Euroapi reported a net loss of €141.5 million for the first half of 2026, compared with a loss of €28.5 million a year earlier, as the company absorbed heavy non-recurring charges tied to its Focus 27 restructuring plan. Net sales fell 13.5% year-over-year to €356.5 million, while core EBITDA dropped to €20.7 million, representing a 5.8% margin versus 9.6% in H1 2025. The bottom line was weighed down by €63.8 million in non-recurring items, including €42.5 million in employee-related expenses linked to a Frankfurt redundancy plan, and €92.6 million in depreciation and amortization that contained €33 million in impairments. The company swung to a net debt position of €37.9 million from a net cash position of €68.2 million at the end of 2025, though it retains substantial liquidity with a €451 million revolving credit facility that has been only lightly drawn. For the full year, Euroapi expects net sales to decline around 10% on a comparable basis and a core EBITDA margin of approximately 6% at constant perimeter, with a roughly €9 million adverse foreign-exchange impact from the Hungarian forint.
Euroapi SASNet loss widened to €141.5M due to restructuring costs and impairments, with sales and EBITDA down.
Sanofi SA